Browsing by Author "Beş, Cemal"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Publication An observational study from the perspective of rheumatology in the management of patients with psoriatic arthritis in Turkey - LOOP study(Wiley, 2021-09-01) Dalkılıç, Ediz; Solmaz, Dilek; Küçükşahin, Orhan; Çapkın, Erhan; Derin, Mehmet Emin; Arslan, Didem; Noyan, Fatih; Coşkun, Nihan Belkıs; Murat, Sadiye; Şendur, Ömer Faruk; Melikoğlu, Meltem Alkan; Gürsoy, Savaş; Kaya, Taciser; Şahin, Ali; Karkucak, Murat; Pırıldar, Timur; Terzioğlu, Mustafa Ender; Beş, Cemal; Akar, Servet; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; CMF-4757-2022; ICV-9647-2023Publication Are there any clues to predict bamboo spine in axial spondyloarthritis?(Wiley, 2020-10-01) Atagündüz, Pamir; Kiraz, Sedat; Akar, Servet; Küçükşahin, Orhan; Erden, Abdulsamet; Beş, Cemal; Kılıç, Levent; Karadağ, Ömer; Kaşifoğlu, Timuçin; Emmüngil, Hakan; Çınar, Muhammet; Kimyon, Gezmis; Yazısız, Veli; Ateş, Aşkın; Ersözlü, Emine Duygu; Gonullu, Emel; Mercan, Rıdvan; Ertenli, İhsan; Kalyoncu, Umut; Yağız, Burcu; YAĞIZ, BURCU; Coşkun, Nihan; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CLH-7318-2022Item Assessment of damage and prognosis in patients with adult iga vasculitis: Retrospective multicentered cohort study(Bmj Publishing Group, 2017-06) Alibaz, Öner; Omma, Ahmet; Sarı, Alper; Karadağ, Ömer; Cansu, Döndü Üsküdar; Beş, Cemal; Yıldız, Fatih; Yılmaz, Sema; Balkarlı, Ayşe; Üreyen, S.; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.Publication Interim analysis of baseline characteristics and preferences of administration route of rheumatoid arthritis patients who are bio-naive or switched between advanced ra treatments; a multicenter, prospective, observational study(Wiley, 2018-09-01) Direskeneli, Haner; Karadağ, Ömer; Ateş, Aşkın; Tufan, Abdurrahman; İnanç, Nevsun; Koca, Süleyman Serdar; Çetin, Gözde Yıldırım; Akar, Servet; Çınar, Muhammet; Yılmaz, Sedat; Yılmaz, Neslihan; Dalkılıç, Ediz; Beş, Cemal; Özbalkan, Zeynep; Yılmazer, Bariş; Şahin, Ali; Ersözlü, Emine Duygu; Tezcan, Mehmet Engin; Şen, Nesrin; Keser, Gökhan; Tansoker, İlkan; Hacıbedel, Fatma Başak; Helvacıoğlu, Kerem; Günay, Levent Mert; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CMF-4757-2022Publication Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022Publication Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.